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1In the past 3 decades, the introduction of renin–angiotensin aldosterone system (RAAS) inhibitors has significantly 
improved morbidity and mortality in chronic heart failure (HF) 
patients with reduced ejection fraction (HFREF).1 Although 
RAAS inhibitors have beneficial effects on the heart and vas-
culature, they also induce a small decrease in renal function as 
estimated by glomerular filtration rate (eGFR). This effect is 
caused by the effect of RAAS inhibitors on renal autoregula-
tion, primarily preventing efferent (post) glomerular arteriolar 
vasoconstriction. This action is often considered to be harmful 
because data from large epidemiological studies and meta-anal-
yses suggest that even a slight decrease in eGFR is associated 
with an increased risk of poor clinical outcomes.2 However, 
this assumption based on associations is too simplistic. In fact, 
a recent meta-analysis showed that even if worsening renal 
function (WRF) occurs during the initiation of RAAS inhi-
bition in patients with HFREF, the mortality benefit is main-
tained, although the net benefit of RAAS blockade may be less 
in patients with WRF because the favorable effects of RAAS 
blockade are partially offset by the risk associated with WRF.3 
However, it is clear that the cause of WRF, rather than its occur-
rence per se, is what seems to be most important, and WRF 
caused by RAAS blockade has been dubbed “pseudo-WRF”.4
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Background—Renin–angiotensin aldosterone system (RAAS) inhibitors significantly improve outcome in heart failure 
(HF) patients with reduced ejection fraction (HFREF), irrespective of the occurrence of worsening renal function (WRF). 
However, in HF patients with preserved ejection fraction (HFPEF), RAAS inhibitors have not been shown to improve 
outcome but are still frequently prescribed.
Methods and Results—Random effect meta-analysis was performed to investigate the relationship between RAAS inhibitor 
therapy, WRF in both HF phenotypes, and mortality. Studies were selected based on literature search in MEDLNE and 
included randomized, placebo controlled trials of RAAS inhibitors in chronic HF. The primary outcome consisted of the 
interaction analysis for the association between RAAS inhibition–induced WRF, HF phenotype and outcome. A total of 8 
studies (6 HFREF and 2 HFPEF, including 28 961 patients) were included in our analysis. WRF was more frequent in the 
RAAS inhibitor group, compared with the placebo group, in both HFREF and HFPEF. In HFREF, WRF induced by RAAS 
inhibitor therapy was associated with a less increased relative risk of mortality (relative risk, 1.19 (1.08–1.31); P<0.001), 
compared with WRF induced by placebo (relative risk, 1.48 (1.35–1.62); P<0.001; P for interaction 0.005). In contrast, 
WRF induced by RAAS inhibitor therapy was strongly associated with worse outcomes in HFPEF (relative risk, 1.78 (1.43–
2.21); P<0.001), whereas placebo-induced WRF was not (relative risk, 1.25 (0.88–1.77); P=0.21; P for interaction 0.002).
Conclusions—RAAS inhibitors induce renal dysfunction in both HFREF and HFPEF. However, in contrast to patients 
with HFREF where mortality increase with WRF is small, HFPEF patients with RAAS inhibitor–induced WRF have an 
increased mortality risk, without experiencing improved outcome with RAAS inhibition.  
(Circ Heart Fail. 2017;10:e003588. DOI: 10.1161/CIRCHEARTFAILURE.116.003588.)
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Although evidence is lacking for a definite benefit of 
RAAS inhibitors in patients with HF with preserved ejection 
fraction (HFPEF), these therapies are frequently prescribed, 
mostly to control blood pressure for other comorbidities 
such as diabetic nephropathy, which are common in HFPEF, 
and for the primary and secondary prevention of cardiovas-
cular events. For example, 84% of patients in the TOPCAT 
(Treatment of Preserved Cardiac Function Heart Failure With 
an Aldosterone Antagonist) study were treated with an angio-
tensin-converting enzyme inhibitor (ACEi) or angiotensin II 
receptor blocker.5 A recent analysis of the Irbesartan in Heart 
Failure with Preserved Ejection Fraction Study (I-Preserve) 
suggested that even WRF caused by RAAS blockade is asso-
ciated with worse outcome in patients with HFPEF.6 However, 
in a retrospective analysis from the CHARM (Candesartan 
in Heart Failure-Assessment of Reduction in Mortality and 
Morbidity) study, differences in HFREF versus HFPEF 
patients with respect to RAAS inhibitor–induced WRF were 
less clear.7
Therefore, we aimed to investigate the interaction between 
the phenotype of chronic HF, treatment with RAAS inhibitors, 
the occurence of WRF and association with clinical outcome 
in a meta-analysis of published studies.
Methods
Literature Search
MEDLINE was searched to identify eligible studies that were pub-
lished from inception to December 1, 2015. We used keywords in-
cluding (but not limited to) heart failure, ACE inhibition, angiotensin 
receptor blocker, mineralocorticoid receptor antagonist, aldosterone 
receptor blockers, renal function, WRF, and outcome. We included 
articles limited to the English language. Furthermore, we searched 
our own files, reviewed reference lists from eligible studies and con-
sulted the Cochrane Library for publications that cited key publica-
tions. The corresponding author was contacted as needed to obtain 
data not included in the published report. As such, we obtained ad-
ditional data from the Val-HeFT (Valsartan Heart Failure Trial), the 
RALES (Randomized Aldactone Evaluation Study), the EPHESUS 
(Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy 
and Survival Study), and the EMPHASIS-HF (Eplerenone in Mild 
Patients Hospitalization and Survival Study in Heart Failure).8–11 
However, we could not obtain data from 3 important trials because 
access was declined by either sponsor or corresponding author.5,12,13 
Data extraction and assessment of studies were done by 2 indepen-
dent authors (IB and KD), and any disagreements were resolved by 
consensus.
Study Selection
Our primary analysis consisted of the following studies: studies in-
vestigating the relationship between randomized, placebo controlled 
RAAS inhibitor therapy, the occurrence of WRF, and subsequent mor-
tality. Articles were excluded for the primary analysis if (1) no crude 
mortality data for the study groups (RAAS or placebo and WRF or 
no WRF) were available even after contact with the authors, (2) data 
were only published in abstract form, and (3) no clear definition for 
HF or specific HF phenotype was given. Any definition for WRF was 
included for this analysis. Data extracted from the study included first 
author name, year of publication, baseline characteristics, including 
medical history, therapy, and most importantly number of patients 
with and without WRF in patients allocated to placebo or RAAS 
inhibition, as well as the outcome (all-cause mortality and HF hos-
pitalization crude numbers) in each of these groups. We performed 
multiple secondary analyses. In parallel to the primary analysis, we 
also evaluated the association with the outcome of HF hospitalization, 
with similar inclusion criteria of studies. Furthermore, we also com-
pared the incidence of “renal dysfunction” between patients allocated 
to RAAS inhibitors or placebo, specified as adverse events, as safety 
end point, or specific trial end point. Also, we evaluated the change in 
eGFR between the 2 treatment groups. For these 2 last analyses, the 
inclusion criteria for studies were different from the primary analysis: 
any study with patients with chronic HF of any phenotype that ran-
domly received an RAAS inhibitor or placebo and had information 
on occurrence of renal dysfunction or change in eGFR available were 
included in the analyses, even if these studies were not included in 
the primary analysis.
Study Quality
The quality of the included studies was assessed using the Cochrane 
Risk of Bias tool, available via http://cochrane.org/.14 This tool is 
developed for meta-analyses of randomized clinical trials, and uses 
qualitative assessment of different domains to assess risk of bias.
Statistical Analysis
Meta-analysis was performed using a random-effects model (Mantel–
Haenszel) to determine risk associated with the presence of random-
ized RAAS inhibitor therapy, incident WRF, and all-cause mortality, 
as measured by combined crude mortality rates. The primary out-
come consisted of the interaction analysis between the association 
of WRF with mortality in the RAAS inhibitor group in the HFREF 
versus the HFPEF population according to Bland and Altman.15 Also, 
the interaction analysis for the association between WRF and mortal-
ity in the placebo group in both HF phenotypes was assessed. For the 
secondary analysis of HF rehospitalization, similar approaches were 
used. For the incidence of renal dysfunction, another random-effects 
model was constructed and interaction analysis for the difference be-
tween HFREF and HFPEF was determined. Change in eGFR was 
evaluated by continuous measures random effects meta-analysis.
For all analyses among study heterogeneity of risk estimates was 
examined using a standard χ2 test and I2 statistic for heterogeneity. I2 
is the percentage of variance that is due to between-study variance. A 
funnel plot was constructed to visually investigate possible confound-
ing of published studies. We performed meta-regression to assess 
possible confounding of the established associations, which included 
all available baseline characteristics of the studies in the primary 
analysis, and the definition (and timing) of WRF used in the indi-
vidual studies. Results are presented as relative risks (RRs) with their 
95% confidence intervals and P values. Odds ratios are presented for 
the risk of WRF in subgroup stratified by RAAS inhibition, placebo 
and HF phenotype. All reported probability values are 2-tailed, and 
a P value of <0.05 was considered statistically significant. Statistical 
analyses were performed using Stata 12.0, College Station, TX, and 
Revman 5.1.16
Results
Our search identified a total of 8 studies investigating the asso-
ciation between RAAS-inhibitor or placebo-associated WRF 
and mortality. Figure 1 shows the Quality of Reportin of Meta-
analysis (QUOROM) diagram of the selection of studies. Of the 
8 included studies, 6 investigated solely HFREF patients,8–11,17,18 
1 investigated only patients with HFPEF,6 and 1 published 
information about both HFREF and HFPEF patients.7 All stud-
ies were graded as sufficient quality. Risk of bias was highest 
for the blinding of outcome assessment, as in most studies it 
was unclear whether investigators were blinded to the develop-
ment of WRF as (intermediate) outcome. (Figure I in the Data 
Supplement) For the primary analysis, 28 961 patients were 
included in the individual studies (24 520 in HFREF and 4441 
in HFPEF). Table 1 shows the baseline characteristics of these 
studies. Mean baseline eGFR was 70±4.1 mL/min per 1.73 m2, 
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with an accompanying serum creatinine of 1.12±0.07 mg/dL 
(99±6.0 μmol/L [7 studies]). Table I in the Data Supplement 
shows the definition of WRF used in each study.
In the overall study population, WRF developed in 3268 
patients (11%) and was more frequent with RAAS inhibition, 
compared with placebo (13 versus 9%).WRF was overall more 
frequent with HFREF (12%) compared with HFPEF (7%). 
However, the excess risk of WRF associated with RAAS-
inhibitor was similar in HFREF (odds ratio, 1.68 [1.25–2.25] 
and HFPEF [odds ratio, 2.03 [1.60–2.57]; P=0.33).
RAAS Inhibitor–Induced WRF and Mortality in 
HFREF and HFPEF
Table 2 shows the crude mortality rates stratified for treatment 
and WRF in each individual study. In HFREF, in patients 
randomized to RAAS inhibitors, WRF was associated with 
worse outcomes, compared with patients who experienced no 
WRF (RR, 1.19 (1.08–1.31); P<0.001) (Figure 2). However, 
the risk associated with WRF in patients allocated to placebo 
was larger (RR, 1.48 (1.35–1.62); P<0.001), and significantly 
different from patients randomized to RAAS inhibitors with 
WRF (P for interaction=0.005).
In HFPEF the pattern was different. In patients with HFPEF 
randomized to RAAS inhibitors WRF was associated with worse 
outcomes compared with those who experienced WRF (RR, 
1.78 [1.43–2.21]; P<0.001). Patients with HFPEF who experi-
enced WRF on placebo had a lower risk of mortality compared 
with patients who did not experience WRF on placebo (RR, 1.25 
[0.88–1.77]; P=0.29), and showed a trend toward a difference with 
those with WRF on RAAS inhibitors (P for interaction=0.092).
The association between RAAS inhibitor–induced WRF and 
outcome was significantly different between HFREF and HFPEF 
patients (P for interaction=0.002). The risk associated with pla-
cebo-induced WRF was similar in HFREF and HFPEF (P for 
interaction=0.34). The funnel plot showed no evidence of publi-
cation bias (Figure 3). Meta-regression did not find any statistical 
significant study characteristics that influenced the study results, 
nor did the definition or timing of WRF affect our findings.
RAAS Inhibitor–Induced WRF and HF 
Hospitalization in HFREF and HFPEF
Similar studies contributed to the end point of HF hospitaliza-
tion, with the exception of the SOLVD (Studies of Left Ventricu-
lar Dysfunction) and Val-HeFT. The total number of patients for 
Figure 1. Quality of Reporting of Meta-analysis diagram of included studies. eGFR indicates estimated glomerular filtration rate; HFPEF, 
heart failure with preserved ejection fraction; HFREF, heart failure with reduced ejection fraction; RAAS, renin–angiotensin aldosterone 
system; RCT, randomized clinical trial; and WRF, worsening renal function.
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this analysis was, therefore, 17 656. Overall, WRF was associ-
ated with more frequent HF hospitalization (RR, 1.44 [1.30–
1.59]; P<0.001), and did not significantly differ between RAAS 
and placebo-induced WRF. Table 2 shows the crude HF hospi-
talization rates stratified for treatment and WRF for individual 
studies. Figure 4 shows the results of the meta-analysis for HF 
hospitalization. WRF was associated with increased risk of HF 
hospitalization in all groups, but most pronounced for RAAS 
inhibitor–induced WRF in HFPEF (RR, 1.64 [1.13–2.39]; 
P<0.001). However, this was not significantly different from pla-
cebo-related WRF in HFPEF (P for interaction=0.47) or RAAS 
inhibitor–induced WRF in HFREF (P for interaction=0.29).
RAAS Inhibitor–Induced, Investigator Reported, 
Renal Dysfunction in HFREF and HFPEF
For this analysis, 12 HFREF and 5 HFPEF studies contributed 
data.5–8,11,12,19–27 Renal dysfunction as adverse event or safety 
end point (and therefore defined by different definitions in 
each study) occurred overall in 3.2% of patients (3.9 versus 
2.6% in RAAS-inhibitors versus placebo; RR, 1.52 [1.24–
1.88]; P<0.001). The incidence of renal dysfunction was simi-
lar in HFREF and HFPEF, and the risk associated with RAAS 
inhibition was similar in both HF phenotypes (P for interac-
tion=0.63; Figure 5).
RAAS Inhibitor–Induced Changes in eGFR in 
HFREF and HFPEF
For change in eGFR, we evaluated change during the entire 
study period, but for each study this time period differed.6–11,26 
Overall, RAAS inhibitor therapy resulted in a greater decline 
in eGFR compared with placebo (mean treatment difference 
-3.61 mL/min per 1.73 m2 Figure 6). The mean treatment dif-
ference in HFREF versus HFPEF for RAAS inhibitors versus 
placebo was similar (P for heterogeneity 0.38).
Figure 2. Forest plot of association between renin–angiotensin aldosterone system (RAAS) inhibition, worsening renal function (WRF), 
heart failure  phenotype, and mortality. CHARM indicates Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbid-
ity; CI, confidence interval; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; EPHESUS, 
Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; HFPEF, heart failure with preserved ejection frac-
tion; HFREF, heart failure with reduced ejection fraction; I-Preserve, Irbesartan in Heart Failure With Preserved Ejection Fraction Study; 
RALES, Randomized Aldactone Evaluation Study; RCT, randomized clinical trial; RR, relative risk; SAVE, Survival and Ventricular Enlarge-
ment; SOLVD, Studies of Left Ventricular Dysfunction; and Val-HeFT, Valsartan Heart Failure Trial.
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Discussion
There are three essential findings of this meta-analysis. First 
is that RAAS inhibitor treatment- induced WRF in both 
phenotypes of chronic HF compared with placebo. Second, 
WRF in patients with HFREF randomized to RAAS inhibi-
tors was associated with slightly worse outcomes compared 
with patients without WRF. However, the incremental risk 
of mortality associated with WRF in patients with HFREF 
allocated to placebo was larger. Likewise, WRF in patients 
with HFPEF randomized to RAAS inhibitors was strongly 
associated with worse outcomes compared with patients 
without WRF.
However, in contrast to HFREF, patients with HFPEF who 
experienced WRF on placebo had a smaller incremental risk 
of mortality (versus placebo treated patients without WRF) 
compared with patients with HFPEF experiencing WRF on 
RAAS inhibition.
RAAS Inhibition and WRF in HFREF
Our findings are consistent with other studies, which dem-
onstrated the deterioration of renal function after the use of 
RAAS inhibitors in patients with HFREF. The CONSEN-
SUS (Cooperative North Scandinavian Enalapril Survival 
Study) demonstrated a reduction in mortality with ACE 
inhibition, despite an enalapril-induced increase in mean 
serum creatinine of 10% to 15% above baseline.19 In the 
SAVE (Survival and Ventricular Enlargement) study, mild 
to moderate chronic kidney disease was associated with a 
heightened risk of all major cardiovascular events, and also 
showed that increases in serum creatinine are frequently 
found in these patients.17 SOLVD observed the same sur-
vival benefit imparted by RAAS inhibitor treatment in 
patients with HFREF, compared with placebo, despite the 
development of early WRF.18 Findings from HFREF studies 
on RAAS inhibitor–induced WRF were meta-analyzed by 
Clark et al.3 In that study, the authors found that patients 
with WRF had overall worse outcomes compared with 
patients without WRF. However, the reduction in all-cause 
mortality associated with the use of RAAS inhibitors was 
significantly greater in the presence of WRF compared with 
the no WRF group. Also, the risk associated with WRF was 
significantly smaller in patients allocated to RAAS inhibi-
tors versus placebo.
Our findings further support and extend the find-
ings by Clark et al. In our present analysis in patients 
with HFREF, which also included data from CHARM 
and EMPHASIS-HF,11,28 we found that RAAS inhibitors– 
induced WRF more frequently compared with placebo. 
Furthermore, WRF was associated with worse outcomes 
(mortality and HF hospitalization) in both the RAAS inhibi-
tor and the placebo groups (compared with no WRF in the 
respective treatment groups), but the survival benefit with 
RAAS inhibitors was largely maintained. In other words, 
WRF induced by RAAS inhibitors was associated with a 
smaller increment in the risk of worse outcomes than WRF 
associated with placebo in patients with HFREF. These 
findings suggest that decreases in eGFR during the upti-
tration of RAAS inhibitors should not immediately lead to 
treatment discontinuation, as there is still likely to be a net 
benefit from treatment.
RAAS Inhibition and WRF in HFPEF
One major limitation of the aforementioned studies and 
meta-analysis is that they did not distinguish between the 
phenotypes of HF and only included patients with HFREF. 
Figure 3. Funnel plot of included studies in primary analysis. HFPEF indicates heart failure with preserved ejection fraction; HFREF, heart 
failure with reduced ejection fraction; RAASi, renin–angiotensin aldosterone system inhibition; and RR, relative risk.
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More recently, a retrospective analysis from the I-Preserve 
found that RAAS inhibitor–induced WRF was associated 
with worse outcomes, compared with placebo-induced 
WRF.6 Retrospective analysis of this question in patients 
with HFPEF in CHARM gave a less clear answer, as in 
that study no statistically significant differences were seen 
between the HF phenotypes, although qualitatively simi-
lar findings to those in I-Preserve were obtained.7 In our 
present meta-analysis, we were able to pool the data on 
I-Preserve and CHARM (HFPEF) and found that RAAS 
inhibitor–induced WRF was strongly associated with worse 
outcomes, and that this was significantly different from 
placebo-induced WRF. Importantly, this difference was 
significantly different from that observed in HFREF. The 
findings of this meta-analysis in patients with HFPEF and 
individual included studies, and the difference observed 
with findings in patients with HFREF may suggest that 
these different phenotypes of HF react differently to RAAS 
inhibition.
RAAS Inhibition, Change in eGFR, Incidence of 
Renal Dysfunction in HFREF Versus HFPEF
Although we found that the outcome related to RAAS-
induced WRF was different between HFREF and HFPEF 
patients, the incidence of WRF was actually slightly lower in 
patients with HFPEF. However, WRF is not the only way to 
assess changes in kidney function, which was the reason to 
evaluate incidence of renal dysfunction as adverse events in 
the individual trials, and investigate change in eGFR. Early 
studies on the effect of, especially, ACE inhibitors in pre-
dominantly HFREF patients showed that RAAS inhibitors 
improve renal blood flow in patients with heart failure, but 
also lead to a significant reduction in GFR.29,30 For patients 
with HFPEF, data on renal hemodynamics are lacking. In the 
current meta-analysis we found that the incidence of renal 
dysfunction associated with RAAS inhibitor use, as reported 
in the original studies, was similar in HFREF and HFPEF 
studies. In both phenotypes, RAAS inhibitors increased the 
risk of renal dysfunction (using any definition) by 50%. For 
Figure 4. Forest plot of association between renin–angiotensin aldosterone system (RAAS) inhibition, worsening renal function (WRF), 
heart failure (HF) phenotype, and HF hospitalization. CHARM indicates Candesartan in Heart Failure-Assessment of Reduction in Mortal-
ity and Morbidity; CI, confidence interval; EMPHASIS-HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; 
EPHESUS, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study; HFPEF, heart failure with preserved 
ejection fraction; HFREF, heart failure with reduced ejection fraction; I-Preserve, Irbesartan in Heart Failure With Preserved Ejection  
Fraction Study; RALES, Randomized Aldactone Evaluation Study; RCT, randomized clinical trial; RR, relative risk; and SAVE, Survival and 
Ventricular Enlargement.
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the change in eGFR early during the treatment with RAAS 
inhibitors, we found that RAAS inhibitor therapy resulted in 
a significant decrease in eGFR compared with placebo. For 
both HFREF and HFPEF, the mean difference in change in 
eGFR between RAAS inhibitor and placebo was around 4 
mL/min per 1.73 m2
Possible Explanations and Clinical Consequences
It is difficult to speculate on the specific underlying mecha-
nisms that cause the apparent difference in outcomes associ-
ated with RAAS inhibitor–induced WRF in both phenotypes 
of HF. One obvious reason could be that the detrimental 
outcome related to WRF is not counteracted by the positive 
effects of RAAS inhibitors in HFPEF and that our findings 
are merely a reflection of the lack of benefit of these com-
pounds in HFPEF. One other reason could be that the risk 
associated with RAAS-induced WRF in HFPEF is larger 
(and different) from that observed in HFREF. This is sup-
ported by the fact that the risk estimates for WRF were indeed 
substantial for WRF in HFPEF. Our data on change in eGFR 
and renal dysfunction, which were similar in HFREF and 
HFPEF, also suggest that these differences cannot only be 
explained by the effect of RAAS inhibition on renal func-
tion and dysfunction. Hypothetically, the pathophysiology of 
renal dysfunction in HFPEF is different from that in HFREF; 
in the latter renal dysfunction has been associated with 
worse renal hemodynamics, whereas more recently, renal 
dysfunction in HFPEF has been attributed to inflammatory 
state and endothelial dysfunction.31,32 Also, a drop in blood 
pressure, induced by RAAS inhibitor therapy, may have dif-
ferential effects on renal function (and subsequent outcome) 
in both phenotypes of heart failure. However, our current 
meta-analysis cannot give definite answers to these impor-
tant questions. One other interesting observation from our 
analyses could be that placebo-associated WRF in HFPEF 
was not associated with increased mortality risk, something 
that goes against observational evidence showing a stronger 
association between WRF and clinical outcome with more 
Figure 5. Association between renin–angiotensin aldosterone system inhibition (RAASi) and renal dysfunction in heart failure patients with 
reduced ejection fraction and heart failure patients with preserved ejection fraction. Renal dysfunction as defined in each individual study 
specified as either adverse event, as safety end point or specific trial end point. AIRE indicates Acute Infarction Ramipril Efficacy Study; 
ALOFT, Aliskiren Observation of Heart Failure Treatment; ARIANA-CHF-RD, Additive Renin Inhibition With Aliskiren on Renal Blood Flow 
and Neurohormonal Activation in Patients with Chronic Heart Failure; ARTS, The mineralocorticoid Receptor Antagonist Tolerability Study; 
ASPIRE, Aliskiren Study in Post-MI Patients to Reduce Remodeling; CHARM, Candesartan in Heart Failure-Assessment of Reduction in 
Mortality and Morbidity; CI, confidence interval; CONSENSUS, Cooperative North Scandinavian Enalapril Survival Study; EMPHASIS-
HF, Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure; HFPEF, heart failure with preserved ejection fraction; 
HFREF, heart failure with reduced ejection fraction; I-PRESERVE, Irbesartan in Heart Failure With Preserved Ejection Fraction Study; PEP-
CHF, Perindopril in Elderly People With Chronic Heart Failure; RR, relative risk; SPICE, Study of Patients Intolerant of Converting Enzyme 
Inhibitors; TOPCAT, Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist; TRACE, Trandolapril Cardiac 
Evaluation Study; and Val-HeFT, Valsartan Heart Failure Trial.
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preserved LVEF in HF.2 For the clinician, the most impor-
tant conclusion from our analysis should be that careful 
assessment of eGFR during uptitration of RAAS inhibitors 
is essential. This also holds for the situation in which these 
therapies are prescribed to patients with HFPEF for whatever 
reason. In those patients, the clinician should be even more 
careful in prescribing, uptitrating, and continuing RAAS 
inhibitor therapy when eGFR decreases, as our analysis sug-
gests that these patients are at extremely increased risk for 
detrimental outcome.
Limitations
The strength of this meta-analysis is that the data were derived 
from high-quality, randomized, controlled trials with over 
25,000 patients, with extensive, high-quality assessments of 
patients and patients outcomes. However, the included data 
were all obtained from post hoc analyses and they should be 
considered hypothesis-generating only. In addition, this was 
a meta-analysis on aggregate data, rather than individual 
patient data, which clearly has its limitations on the general-
izibility. The definition of WRF and timing of the assessment 
of follow-up creatinine differed substantially between the 
included studies. Furthermore, aggregate data meta-analysis 
cannot account for possible selection bias in the individual 
studies. For instance, patients who had an event before a sec-
ond creatinine was drawn will not have been included in this 
meta-analysis. These differences could have affected our main 
findings. Another limitation of this meta-analysis is that we 
pooled different types of RAAS inhibitors: ACE inhibitors, 
angiotensin II receptor blockers, and mineralocorticoid recep-
tor antagonists, whereas the latter could not be considered for 
HFPEF. Because their pharmacological working mechanisms 
differ, a difference in outcome could be expected as well. Our 
study included only 2 HFPEF trials, and therefore the assess-
ment of heterogeneity in this subset of the analyses should be 
interpreted with caution. Also, our findings need replication in 
a larger (prospective) study to confirm our study results of a 
difference between HFREF and HFPEF patients on this sub-
ject. Finally, our analyses were carried out in a specific subset 
of patients, which included post myocardial left ventricular 
dysfunction, and specifically investigated WRF during ini-
tiation of (additional) RAAS-inhibition, not during long-term 
follow-up.
Conclusions
RAAS inhibitors cause a significant decline in eGFR and 
lead to more renal adverse events with similar magnitude in 
both HFREF and HFPEF patients. Despite this fact, although 
RAAS inhibitor–induced WRF in HFREF is associated with 
slightly increased event rates, the prognostic benefit over 
placebo-induced WRF is maintained. However, in HFPEF, 
especially WRF that occurs with RAAS inhibition seem det-
rimental, cautioning the clinician to carefully evaluate these 
HFPEF patients with increases in creatinine during RAAS 
inhibitor treatment.
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CLINICAL PERSPECTIVE
Renin–angiotensin aldosterone system (RAAS) inhibitors are the cornerstone treatments of heart failure patients with 
reduced ejection fraction (HFREF), but have failed to live up to their expectations in heart failure with preserved ejection 
fraction (HFPEF). However, these therapies are still being used in patients with HFPEF, especially as secondary prevention. 
RAAS inhibitors frequently induce worsening renal function (WRF). This meta-analysis investigated a possible interaction 
between the phenotype of heart failure (HFREF versus HFPEF) and the association between RAAS inhibitor–induced WRF 
and clinical outcome. In both HFREF and HFPEF, RAAS inhibitor therapy was associated with a significant fall in estimated 
glomerular filtration rate and higher incidence of renal dysfunction. Despite these effects on renal function, RAAS inhibitor–
induced WRF was not associated with worse outcomes in patients with HFREF. In contrast, in patients with HFPEF, espe-
cially, RAAS inhibitor–induced WRF related to higher event rates. These findings point toward an important differential 
effect of RAAS inhibitor–induced WRF in HFREF versus HFPEF patients. Because these therapies are widely prescribed 
in the entire cardiovascular population, including patients with HFPEF, clinicians should be aware of the clinically relevant 
WRF when treating these patients with RAAS inhibitors. In contrast to patients with HFREF where significant deteriorations 
in renal function can probably be accepted as long as the clinical course of the patient is favorable, any RAAS inhibitor–
induced WRF in patients with HFPEF should be regarded as important. Patients with HFPEF receiving these drugs should 
be monitored closely with respect to their renal function, and dose adjustment or discontinuation should be considered when 
WRF develops.
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SUPPLEMENTAL MATERIAL 
 
Supplementary Table 1. Definition of Worsening Renal Function in included studies 
Study Change in creatinine/eGFR During Follow Period 
SOLVD1 20% decrease in eGFR 2 weeks after randomization 
SAVE2 ≥ 0.3 mg/dL increase 2 weeks after randomization 
RALES3 30% decrease in eGFR 12 weeks after randomization 
Val-HeFT4 20% decrease in eGFR 4 weeks after randomization 
CHARM5 ≥ 0.3 mg/dL increase ánd ≥ 25% increase in serum creatinine 6 weeks after randomization 
EPHESUS6 20% decrease in eGFR 2 weeks after randomization 
I-PRESERVE7 ≥ 0.3 mg/dL increase ánd ≥ 25% increase in serum creatinine 8 weeks after randomization 
EMPHASIS-HF8 20% decrease in eGFR 5 months after randomization 
 
Abbreviations: eGFR: estimated Glomerular Filtration Rate. CHARM: Candesartan in Heart 
Failure-Assessment of Reduction in Mortalityand Morbidity, EMPHASIS-HF: Eplerenone in Mild 
Patients Hospitalization and Survival Study in Heart Failure, EPHESUS: Eplerenone Post–Acute 
Myocardial Infarction Heart Failure Efficacy and Survival Study, I-PRESERVE: Irbesartan in 
Heart Failure with Preserved Ejection Fraction Study, RALES: Randomized Aldactone Evaluation 
Study, SAVE: Survival And Ventricular Enlargement Study, SOLVD:Studies Of Left Ventricular 
Dysfunction, Val-HeFT: Valsartan Heart Failure Trial 
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